Clinical trials: Durvalumab
HCC - Hepatocellular Carcinoma, Durvalumab
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
- Trial name
- Proton-STRIDE (NCT06999694)
- Testing
- Proton radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
The purpose of this study was to evaluate the efficacy of low-dose radiotherapy (LDRT) combined with durvalumab, etoposide, and cisplatin/carboplatin in the first-line treatment of extensive-stage small cell lung cancer.
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
- Trial name
- NCT05092412
- Testing
- Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- You Lu
Intrahepatic Cholangiocarcinoma (Icc), HAIC
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
- Trial name
- HAIC-quad (NCT06859684)
- Testing
- Durvalumab, hepatic arterial infusion chemotherapy (HAIC), Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
HCC - Hepatocellular Carcinoma, Immunotherapy
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals
This study aims to evaluate the response to immunotherapy in HCC, assess the toxicity profile and measure overall survival within the study period.
- Conditions
- HCC - Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Therapy, Immune Checkpoint Inhibitor-Induced Dermatitis
- Trial name
- NCT07088081
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Pulmonary sarcomatoid_MEDI4736+Treme
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
- Trial name
- NCT03022500
- Testing
- durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Hospital
Bladder Cancer, High-Risk Cancer
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder cancer will stimulate an effective…
- Conditions
- Bladder Cancer, High-Risk Cancer, Tremelimumab, Durvalumab
- Trial name
- Rideau (NCT05120622)
- Testing
- Tremelimumab
- Where
- Canada
- Sponsor
- University of British Columbia
Oncology, Biomarker
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
This non-interventional single-center explorative biomarker study aims at longitudinal comprehensive characterization (molecular genetics, immunological, morphological, image-based and microbial features) of the patient (host)…
- Conditions
- Oncology, Biomarker, NSCLC, Stage III, Durvalumab
- Trial name
- PRECISION (NCT05027165)
- Testing
- Non-interventional
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- LMU Klinikum
Durvalumab, Intrahepatic Cholangiocarcinoma
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
- Conditions
- Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis
- Trial name
- NCT05672537
- Testing
- Durvalumab, Surgery, Gemcitabine
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer, Small Cell Lung Cancer
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
The purpose of this study was to evaluate the efficacy and safety of combining durvalumab with EP followed by durvalumab + olaparib maintenance therapy as first-line treatment in patients with extensive-disease small-cell lung…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Durvalumab
- Trial name
- NCT05245994
- Testing
- Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Li Zhang, MD
Leptomeningeal Metastasis, Durvalumab
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis
- Trial name
- NCT04356222
- Testing
- Durvalumab, methotrexate
- Volunteers
- 30 people
- Sponsor
- Hui Bu
Anlotinib, Durvalumab
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
- Conditions
- Anlotinib, Durvalumab, Small Cell Lung Cancer
- Trial name
- NCT04314297
- Testing
- Anlotinib In Combination With Durvalumab
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology